Clinical Trial Update: Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC [Phase 3]

View source ↗

Summary

A Phase 3 trial update comparing cetuximab to cisplatin in HPV-positive oropharyngeal squamous cell carcinoma, focusing on early and late toxicity; trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• ERBITUX (cetuximab)

Snippet

Sponsor: University of Warwick | Conditions: Oropharyngeal Squamous Cell Carcinoma | Phase 3 | Status: UNKNOWN